Two drugs commonly prescribed to treat type 2 diabetes carry a high risk of cardiovascular events such as heart attack, stroke, heart failure or
In the largest trial of its kind to determine the cardiovascular outcomes for a new class of diabetes medications, Astra Zeneca’s Farxiga was
Eli Lilly and Company reported that it’s drug, Trulicity® significantly reduced major adverse cardiovascular events, a composite endpoint of
Metformin, a commonly prescribed drug for type 2 diabetes could prevent heart disease in patients with type 1 diabetes -and could lead to the
Eli Lilly and Company’s investigational two-in-one diabetes drug showed both meaningful blood sugar reduction and significant weight loss in
A weight loss drug, lorcaserin, was found to reduce the risk of diabetes by 19 percent in patients with prediabetes in a recent study. The drug is
Tresiba®, an insulin degludec injection, has received an expanded approval for the treatment of Type 1 diabetes in pediatric patients in Canada.
Should metformin remain first-line therapy for type 2 diabetes? It was one of the more light-hearted but hotly-debated presentations at this
Break-through results in treating patients with type 1 diabetes in a long-term, Harvard and Massachusetts General Hospital study were published
By Wil Dubois The problem with proteins is that they digest quite nicely. That’s not a problem when the protein is a T-Bone steak, but what if the
Get a little dLife delivered to your inbox every week.
Leave this field empty if you’re human: